Premium
Pharmacogenetic Testing: Time for Clinical Practice Guidelines
Author(s) -
Amstutz U,
Carleton BC
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.18
Subject(s) - pharmacogenetics , clinical pharmacology , clinical practice , drug , medicine , genetic testing , drug reaction , pharmacology , drug response , adverse effect , intensive care medicine , medical physics , family medicine , biology , gene , genetics , genotype
Our knowledge regarding genetic factors that affect drug effectiveness and adverse drug reactions is continuously increasing, and a growing number of pharmacogenetic gene–drug interactions are included in drug labels. Nevertheless, the uptake of this important information into clinical practice has been minimal. The development of concise, evidence‐based clinical practice guidelines (CPGs) on pharmacogenetic testing is urgently needed to overcome the barriers hindering clinical implementation by providing guidance on test use and interpretation. Clinical Pharmacology & Therapeutics (2011) 89 6, 924–927. doi: 10.1038/clpt.2011.18